Simplify Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Simplify Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-8,489	Closed	-$597K	–	100
2024 Q3	$597K	Buy	8,489 +3,422	+68%	+$286K	0.03%	86
2024 Q2	$417K	Buy	+5,067	New	+$422K	0.03%	89

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Simplify Asset Management's BMRN Position: Q4 2024 in Review

Simplify Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2024, closing a stake of 8,489 shares — an estimated $597K sold.

Simplify Asset Management first reported a position in BMRN in Q2 2024 and held it in 2 quarters. The position peaked at $597K in Q3 2024. 543 funds tracked by Wall St. Rank hold BMRN as of Q4 2024.

Simplify Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Simplify Asset Management sold 8,489 BioMarin Pharmaceuticals shares in Q4 2024, an estimated $597K.
Simplify Asset Management first reported a position in BioMarin Pharmaceuticals in Q2 2024 and held it in 2 quarters.
Simplify Asset Management's BioMarin Pharmaceuticals position peaked at $597K in Q3 2024.
543 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2024.

Based on Simplify Asset Management's 13F filing for Q4 2024, filed 11 Feb 2025.